proposed that viral deletion mutants that conditionally self-renew at the expense of the wild-type virus (i.e., Defective Interfering Particles, DIPs 1 ) could constitute a longterm intervention that circumvents adherence challenges and has a high genetic barrier to resistance, echoing recent approaches 2 . Theories predict 3,4 that DIPs could be engineered into a therapy for HIV-1 (i.e., Therapeutic interfering particles or 'TIPs') provided they stably persist in patients (R0>1) by spreading to new cells during active infection (hence, a self-replenishing antiviral). To date, DIPs amenable to such engineering have remained elusive for HIV-1. Here we report the discovery of an HIV-1 DIP and its subsequent engineering into a TIP. The TIP interferes with HIV-1 replication at multiple stages of the viral lifecycle, including genome packaging, virion maturation, and reverse transcription, essentially acting as a combination antiviral.
challenging, due in part to deployment, behavioral, and mutational barriers [7] [8] [9] . It has been proposed that Defective Interfering Particles (DIPs) could overcome these barriers 3, 4, 10, 11 .
Originally observed for influenza virus in the 1940s by von Magnus 12 , DIPs are viral deletion mutants that conditionally replicate (i.e., lack self-replication) and act as molecular parasites of the wild-type virus within infected cells, stealing essential proteins from wild-type virus (e.g., replication or packaging proteins). Consequently, DIPs suppress wild-type viral burst size (the number of viral particles released from an infected cell) and conditionally mobilize their own genomes, spreading their antiviral properties to new cells. Mathematical models predicted that DIPs could be long-acting therapeutics against HIV provided they can be synthetically engineered to that have a basic reproductive ratio [R0]>1, which have been called Therapeutic Interfering Particles (TIPs) 3, 4 (Fig. 1a,b ). R0 is a threshold value defined as the expected number of secondary infections arising from a single infected individual or cell 13 ; a spreading infection has an R0>1 while the infection dies out at R0<1. The R0 has been used to define the threshold for TIP persistence; the TIP therapy will 'spread' through the host-cell population when R0 TIP >1 3, 4, 11 . Previous work identified retroviral vectors with the potential to suppress HIV replication [14] [15] [16] [17] [18] , but a number of shortcomings, including suboptimal persistence, limited their translation into therapy 15, 19 .
To understand why mobilizing DIPs might be rare for HIV-unlike other RNA viruses where DIPs are readily isolated in high-MOI passage 12,20 -we used established in silico models of HIV in vivo dynamics 21, 22 . The model predicted that a DIP spontaneously generated on day one would require 50-100 days of continuous culture to reach detectable levels ( Supplementary Fig. 1a and Supplementary Methods) and would fail to expand in conventional serial-passage cultures where DIP-integrated cells would be diluted by exogenous replacement of new target cells. Based on these predictions, we designed an in vitro continuous-culture reactor ( Supplementary Fig. 1b,c and Supplementary Methods) where CD4+ target cells are replenished exclusively by cell division. This reactor enabled long-term HIV culturing and allowed putative DIP-integrated cells to expand without dilution from exogenous replacement of cells.
The reactor was infected with an HIV GFP reporter virus and over the course of ~90 days HIV dynamics, tracked by viral GFP expression, exhibited von Magnus-like fluctuationsstereotyped waves of viral amplification and collapse indicative of DIP formation 23 (Fig. 1c , top). Integrated HIV proviral DNA from a late time point (day 71) was analyzed by PCR and revealed that a nearly 2.5kb region had been deleted from the viral genome (Fig. 1c, middle and bottom) and sequencing mapped this deletion-designated the "F1" deletion (for reactor "Flask #1")-to the pol-vpr region of HIV. A similar deletion arose in a parallel reactor and sequence analysis showed that these deletions were flanked by short homology regions, indicating a likely recombination event ( Supplementary Fig. 1d ).
To test if the F1 deletion variant satisfied the requirements for a DIP (Fig. 1b) , the F1 deletion was cloned into a GFP-tagged HIV backbone ( Supplementary Fig. 2a ), hereafter termed "F1", and its interaction with HIV characterized in cell culture.
First, to test if F1 satisfied the conditional-replication requirement, we provided the deleted HIV-1 proteins to F1 by co-transfection with a packaging plasmid and quantified transduction-competent viral-like particles (VLPs). As expected, F1 only generated transduction-competent VLPs when the deleted HIV-1 proteins were provided in trans (Fig.   1d ).
Second, to test F1's ability to interfere with HIV, we used established approaches 24 to generate an F1-transduced cell line-in which F1 RNA is expressed from single, polyclonal integration sites and is transactivated by HIV Tat protein delivered in trans by HIV superinfection ( Supplementary Fig. 2a ,b)-and measured the outgrowth of BFP-tagged HIV from these cells (for gating scheme see Supplementary Fig. 2c ). Cells with and without F1 appeared equally permissive for initial HIV infection (see Fig. 1e and Supplementary Fig. 2d ), but the subsequent outgrowth of HIV was restricted in the F1integrated cell line, suggesting that F1 interfered with the spread of HIV. Titers of singleround infections also supported F1 interference with HIV; F1 reduced HIV titers by 94% in a single round of infection (p = 5 x 10 -6 ) ( Fig. 1e , inset) whereas no interference was observed in cell lines transduced with lentiviral vector controls ( Supplementary Fig. 3a,b ). To be sure that F1-associated interference was not cell-line dependent, we tested F1 interference in a more permissive T-cell line, MT-4 cells ( Supplementary Fig, 3c ), as well as human primary CD4+ T cells ( Supplementary Fig. 3d ) and found F1 significantly reduced HIV outgrowth in both settings.
Finally, to test if F1 RNAs mobilize in the presence of HIV (e.g., via stealing of packaging proteins from full-length HIV), we analyzed the packaged RNA from single-round infections (titered in Fig. 1e ) by allele-specific qPCR. F1 RNA was present in extracellular VLPs and represented 60% of the total RNA population, showing a packaging advantage over HIV genomes (Fig. 1f, left) .
Overall, these data verify that the F1 construct conditionally replicates (only in the presence of HIV), interferes with HIV outgrowth, and mobilizes from infected cells-thereby constituting a bona-fide DIP. However, despite F1's packaging advantage, F1 exhibited a transmission defect, constituting only 30% of integrated provirus in the subsequent round of infection ( Fig. 1f , right). Since TIP persistence and efficacy depend upon high R0 TIP , we sought to improve transmission efficiency of the F1 construct.
In an effort to rationally enhance F1 transmission efficiency, we next examined F1's genetic sequence. Given the location of the F1 deletion, which spans HIV's central polypurine tract (cPPT), we hypothesized that the loss in transmission efficiency could be due to a reverse transcription or integration defect, since the cPPT has been shown to enhance lentiviral vector transduction efficiency 25-29 and a recent forward genetic screen argues that the cPPT may be even more critical for viral transmission than previously appreciated 30 . Thus, we reintroduced the cPPT back into the F1 construct (hereafter termed "F1 cPPT " ; Fig 2a) . F1 cPPT generated a two-fold increase in VLP-transduction efficiency relative to F1 ( Fig. 2b ), in agreement with previously-published work 28 . We also created a derivative of F1 cPPT , designated "F1 cPPT D," in which additional coding sequence was deleted to ablate extraneous protein expression ( Fig. 2a ) and this construct displayed even greater increase in VLP transmission, with a three-fold increase in transduction efficiency compared to F1 (Fig. 2b ).
We confirmed that both engineered constructs retained the properties of a DIP including conditional replication and packaging (i.e., they did not mobilize between cells, except in the presence of HIV), as well as interference with HIV outgrowth ( Supplementary Fig. 4a -c).
To test if the new F1 cPPT constructs met the requirement for TIP persistence (R0 TIP >1), we developed an assay to directly measure R0 (Fig. 2c ). In brief, cells were stably transduced with a single copy of F1 cPPT D-GFP (integrated at polyclonal loci) and then infected with HIV-BFP to become "producer" cells. These producer cells were then co-cultured with an excess of susceptible mCherry + "target" cells so that single-round HIV and F1 cPPT D transmission into target cells could be quantified from the fractions of BFP + /mCherry + and GFP + /mCherry + cells, respectively. Specifically, the appearance of double-positive GFP + /mCherry + cells indicated transmission of the F1 cPPT D construct from the producer cells to the target cells and the fraction of these double-positives allowed R0 TIP to be calculated ( Fig. 2c ; colors in the schematic do not match fluorophores to maintain consistent designation of F1 as blue and HIV as red). To test whether the assay yielded physiologically relevant R0 values, we measured the R0 of HIV alone (i.e., in the absence of F1 cPPT D) and found that the value (R0 HIV =24) was similar to upper estimates of R0 in vivo 22, 31, 32 . Quantifying the number of F1 cPPT D transmission events after a single round of HIV infection yielded R0 TIP = 12 for F1 cPPT D ( Fig. 2d ), satisfying the requirement for TIP persistence 3, 4, 11 .
We further verified that F1 constructs could persist over multiple rounds of infection by monitoring the transmission of the F1-GFP signal into mCherry + target cells in reactor cultures. Both the F1 cPPT D and F1 cPPT variants exhibited substantial transmission into target cells, showing an exponential rate of increase that was ~6-fold faster than HIV over multiple rounds of infection ( Fig. 2e , Supplementary Fig. 4d ,e). Since F1 constructs did not affect cell growth or survival rates ( Supplementary Fig. 4f -h), the increase in F1-GFP + cells is likely due to efficient mobilization of the F1 constructs.
To test if the engineered F1 variant could persistently reduce viral load, we analyzed multiweek reactor infections where 50% of cells were pre-transduced with F1 cPPT . While the infection in the control flask (100% naïve cells) increased over time, reaching a 28% infection frequency by 22 days post infection, the frequency of infection in the F1 cPPT culture hovered around 1-2% throughout the same timeframe ( Fig. 2f ). Even beyond the first three weeks, HIV infection frequency in the F1 cPPT culture never increased above 5%, demonstrating that F1 cPPT can restrict the outgrowth of HIV by about 10 fold over the course of weeks.
Next, we investigated the mechanism of F1-mediated interference. First, we tested if the F1deletion interferes with HIV outgrowth by stealing HIV packaging resources 3, 4, 11 (Fig. 3a , left panel). Deleting the Y genome packaging signal 33 in F1 cPPT D (Fig. 3b ) reduced F1-associated interference by about 40% but did not completely rescue HIV titers ( Fig. 3c and Supplementary Fig. 5a,b ), suggesting that F1 RNA packaging provides substantial interference but that additional mechanisms must account for the remaining reduction in HIV burst size.
Since the F1 deletion truncates the reverse transcriptase (RT) gene ("RT trunc ," Fig. 3b ) and pure F1 VLPs do not display RT activity ( Supplementary Fig. 5c ), we tested if the presence of F1 reduced RT activity in virions released from HIV-infected cells. Not only did F1 cPPT D reduce virion-associated RT activity ( Fig. 3d ), RT trunc proteins were found in purified F1 VLPs ( Supplementary Fig. 5d ,e) suggesting that defective RT trunc may compete with wild-type RT for virion access and/or RNA templates and subsequently fail to complete reverse transcription ( Fig. 3a , right panel). Knocking out translation 34 of RT trunc in either the F1 cPPT or F1 cPPT D background reduced F1-associated interference by 22% ( Fig. 3e , Supplementary   Fig, 5f ), suggesting that the RT trunc protein also contributes to the reduction in HIV titers.
Having accounted for a portion of F1-mediated interference, the literature suggested a third possible avenue for interference: protease defects. Truncations in the RT sequence are known to reduce protease activity 35 and catalytically-dead proteases trans-dominantly interfere with virion maturation by failing to cleave the Gag structural proteins 36 ( Fig. 3f , Gag cleavage cascade). While the presence of F1 did not affect HIV virion assembly and budding-supernatant concentrations of Gag ( Fig. 3g and Supplementary Fig. 5g ) and the gRNA:Gag ratio ( Fig. 3h and Supplementary Fig. 5h ) were unchanged-Western blot analysis revealed a severe defect in Gag proteolytic cleavage ( Fig. 3i ), similar to that observed in catalytically dead protease mutants ( Supplementary Fig. 5i ). Consistent with the fact that Gag processing defects are potent dominant negatives 37,38 , the presence of wild-type protease did not fully rescue the Gag processing defect (see lanes 2-4 in Western blot, Fig.   3i ), suggesting that F1 may interfere with HIV transmission by arresting virions in the immature, non-infectious state ( Fig. 3a , middle panel).
In sum, F1 appears to interfere with the outgrowth of HIV via at least three distinct points in the viral lifecycle: genome packaging, virion maturation, and reverse transcription, mimicking a combination therapy. Some of the interference appears to involve dominantnegative interactions, which are reported to have a high barrier to therapeutic resistance 39, 40 .
Given that F1 cPPT and F1 cPPT D exhibit similar packaging efficiency, HIV interference levels, ( Supplementary Fig. 4a -c), and interference with RT ( Fig. 3e vs Supplementary Fig. 5f ), the relative breakdown of F1-mediated interference mechanisms is likely not specific to a particular F1 construct.
We next tested the therapeutic effect of the engineered F1 constructs in a humanized mouse model 41,42 used in preclinical trials for new HIV therapies. In this model, hu-PBL mice are engrafted with human CD4+ T cells and subsequently infected with HIV. CD4+ T cell counts decline over the course of a few weeks due to virally-induced cell death, and we hypothesized that mice engrafted with F1-transduced cells should maintain their CD4+ T cell population compared to controls (see Fig. 4a for experimental timeline). As expected, CD4+ T cell counts declined in HIV-infected mice within two weeks. However, mice that received F1 cPPT or F1 cPPT D-transduced cells retained their CD4+ T cell population ( Fig. 4b , p ≤ 0.003, see Supplementary Fig. 6a for gating scheme). The T cell protection in F1-treated mice correlated with a one-log suppression in viral load that occurred a week prior to the observed difference in T cell counts ( Fig. 4c , p ≤ 0.0001), suggesting that the lower viral load prevented T cell depletion. F1-associated T cell maintenance was also observed in an independent cohort, confirming the therapeutic effect of the F1 construct ( Supplementary  Fig. 6b ). We also observed F1 RNAs in the serum (Fig. 4d ), indicating that engineered F1 constructs mobilized within the mouse. In some animals, F1 RNAs accounted for greater than 50% of serum RNAs despite the fact that only ~50% of engrafted cells were transduced with F1 constructs. These data suggest that F1 constructs may be a viable avenue to suppress HIV, though long-term in vivo efficacy will require further testing.
Overall, the data presented here provide proof-of-concept for a class of biologic that can conditionally self-renew and thereby has the potential to be developed into a singleadministration therapeutic. The data indicate that F1 cPPT variants meet the definition of a TIP: they self-replenish by conditionally transmitting between cells with R0>1, display sustained inhibition of HIV in culture, and prevent CD4+ T cell depletion in a pre-clinical humanized-mouse model. Despite only ~1% of cells being productively HIV infected at any given time during asymptomatic infection in vivo 22,43 , established HIV dynamics models indicate that the rapid daily turnover of this 1% of HIV-infected cells would enable TIPs with an R0>1 to co-infect sufficient numbers of cells thereby reducing viral set point by 1-2 Logs 3,4,10,11 -similar to rationales explaining rapid HIV recombination despite most cells harboring a single HIV provirus 44 .
A potential criticism is that TIPs, unlike antiretroviral therapies, do not reduce HIV's in vivo R0 below 1. However, models indicate that if TIPs forced HIV's R0 below 1, TIPs would be unable to maintain R0>1 and therefore would not persist, allowing HIV to reestablish pretreatment viremia levels after rebound from latency 3, 4, 10, 11 . The models further predict that TIPs with R0>1 would possess unique therapeutic capacities including the ability to efficiently access difficult-to-reach high-risk populations, surmount behavioral and adherence barriers, and circumvent mutational escape by establishing co-evolutionary arms races with HIV. Notably, epidemiological models 4, 10 indicate that despite antiretroviral therapy blocking TIP activity at the individual-patient scale, at the population scale TIPs would primarily target high-risk groups where therapy coverage is low and would thus compliment ongoing antiviral campaigns.
Clearly, the long-term efficacy of TIPs will need to be addressed, including whether the R0 is sufficient to control viral loads in a reasonable amount of time in vivo, when and how TIPs should be introduced in vivo for maximal efficacy, and the co-evolutionary dynamics of HIV and TIPs 45 . In addition, the safety of TIPs-both genotoxicity due to TIP integrations and immunotoxicity due to TIP viral loads-will need to be experimentally addressed. We and others have speculated that TIPs may be no more detrimental in patients than the large reservoir of defective proviruses 46,47 since TIPs are constructed solely from sequences already found in HIV and, regarding genotoxicity, clinical studies indicate that integrating lentiviral gene therapies do not generate an increase in T cell cancers [48] [49] [50] . While recombination between HIV and TIP (or existing defective proviruses) is a potential concern and will need to be thoroughly examined, the large internal deletion in F1 reduces the efficiency of recombination, and the most likely recombination product is replicationcompetent HIV 11 , which will only be generated if HIV is present and would thus be equivalent to a conventional loss of therapeutic efficacy. Future studies will determine if the ability of F1 cPPT vectors to simultaneously interfere with HIV and enhance their own VLP production are separable properties, and if the potential for independent genetic re-assortment of these properties exists.
From the standpoint of evolutionary dynamics, one question is why F1-like TIPs have not been detected in vivo despite the well-known abundance of defective HIV genomes 46,47 or previously selected in vitro. A potential explanation could be that for such deletions to accumulate requires an R0>1, which necessitates an unlikely series of recombination and genome-rearrangement events where the cPPT is retained or reinserted whilst specific flanking sequences are deleted 47 .
Finally, the reactor selection result ( Fig. 1c) , where host cells ultimately recovered from HIV infection by integrating a defective viral sequence into their genomes (a phenomenon we have observed repeatedly in culture), is particularly intriguing. Similar in vitro reactor systems may provide a model to recapitulate and examine real-time host cooption or "exaptation" of endogenized retroviral sequences for antiviral defense 51 , or protein repurposing that is common to host-pathogen arms races 52,53 . Ultimately, these selection schema may enable discovery of defective variants that can be reengineered into countermeasures that suppress viral resistance, echoing recent advances in phage therapy 2 .
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Perelson TIPs must mobilize to more than one naïve cell (R0>1) in the presence of HIV. c, Detection of an HIV deletion variant in long-term culture. Top: cell concentration and frequency of GFP + cells in long-term reactor culture. CEM CD4+ cells (hereafter "CEMs") were maintained at steady-state growth in a reactor by daily replacement of approximately 25% of the total culture volume with fresh media ( Supplementary Fig. 1b ) prior to infection with HIV (day -14 to day 0, not shown). On day 0, reactor was infected with HIV-GFP -molecular clone NL4-3 encoding a GFP reporter in the nef reading frame -at low MOI and cells were collected for analysis at regular intervals. Middle: PCR products obtained from integrated HIV proviral DNA. Total DNA was extracted from reactor cells on day 71 and analyzed with primers to the HIV proviral sequence (lane 3). Both the expected band (see HIV plasmid PCR, lane 2) and a band approximately 2.5 kb smaller are indicated on the gel image, which has been cropped to show relevant lanes and bands. Bottom: the "F1 deletion" mapped onto the HIV parent backbone. The location of the deletion was identified by submitting the small PCR band for Sanger sequencing. d, Transduction competence of F1 VLPs assembled in the presence and absence of packaging plasmid. The F1 deletion was cloned into the HIV-GFP backbone [construct name: F1(+Tat)], and the plasmid was transfected into 293T cells in the absence or presence of the Δ8.91R packaging plasmid and pseudotyped with VSVG to generate VLPs. VLPs were titered on permissive MT-4 cells by flow cytometry for GFP. Replication-competent HIV-GFP and a lentiviral reporter vector that expresses GFP from the EF1A promoter (pLEG, see table of constructs) were included as controls. e, Outgrowth of HIV in the presence and absence of the F1 construct. A F1-GFP cell line, transduced with single integrations of F1-GFP (at polyclonal loci), or a mock-transduced control, were infected with HIV-BFP at low MOI. The frequency of BFP + cells was measured by flow cytometry at indicated timepoints. Inset: Filtered supernatants, harvested at 3 dpi, were titered by flow cytometry (48 after infection of naïve cells). Main panel: *p = 0.004 (4 dpi), p = 0.001 (5 dpi), p = 0.001 (7 dpi); Inset: **p = 5 x 10 -6 . All p values obtained using a twotailed, unpaired Student's t test. f, The fraction of F1 and HIV packaged genomic RNA in filtered supernatant (left) compared to the fraction of transmitted proviral DNA that integrated into new cells in a second round of infection (right). gRNA in the supernatant was analyzed by allele-specific RT-qPCR from samples panel e (inset). The transmitted DNA was measured by infecting MT-4 cells as if to titer (as in e), harvesting gDNA at 2 dpi (to allow for integration of WT and F1 constructs) and quantifying by allele-specific qPCR. All data represent the mean and s.e.m. of three biological replicates except in panel c. For long-term reactor culture data in panel c only one reactor trajectory is shown because trajectories and oscillations varied widely between reactors; trajectories for parallel reactors available on request.
Figure 2:
Engineering the F1 DIP into a TIP. a, Construct schematics for full-length HIV, the original F1 DIP construct and engineered F1 constructs. The central polypurine tract (cPPT) was added to enhance transduction efficiency in "F1 cPPT " and protein coding sequences were deleted to reduce extraneous HIV protein expression in "F1 cPPT Δ." For most experiments, HIV has a BFP reporter and the F1 construct has a GFP reporter. Stop mutations were added to the first exon of Tat in F1 cPPT to reduce F1 transcription in the absence of co-infecting virus 54 . The first Tat exon is deleted in F1 cPPT Δ. b, Transduction efficiency of optimized F1 constructs. F1 constructs, packaged as described in Fig. 1 , were titered on permissive MT-4 cells and normalized to p24 (i.e., capsid protein) content. The transduction efficiency of F1 was set to 1. Data represent mean and s.e.m. of three biological replicates, *p = 0.007 and 0.003 for F1 cPPT and F1 cPPT Δ, respectively, by a two-tailed, unpaired Student's t test. c, Assay for mobilization of F1 constructs. Left, experiment schematic: CEM 'producer' cells stably transduced with F1 cPPT Δ-GFP or a UBC-GFP control lentiviral vector were infected with HIV (or mock infected, "HIV -") and at 2 dpi, co-cultured 1:20 with an MT-4 cell line transduced with an EF1A-mCherry cassette (i.e., 'target' cells). Right, cells were analyzed by flow cytometry 3 days post co-culture to determine whether the F1 or control constructs (GFP + ) mobilized into mCherry + target cells in the presence or absence of HIV (see red box for dual positives). d, R0 measurement of F1 cPPT Δ. Assay setup was similar to panel c except that the target cells were CEM cells stably transduced with a dox-inducible Tat-mCherry construct. These target cells were modified to express Tat so that all transmitted F1 cPPT Δ constructs could be detected even in the absence of co-infecting HIV. To measure R0, 95,000 dox-induced Tat-mCherry target cells were co-cultured with 5,000 cells that had been stably transduced with a single copy of Supplementary Table 1 ) and then infected with HIV-BFP at low MOI. BFP + cells were monitored by flow cytometry over time. Control culture data are omitted after 22 dpi because the culture collapsed, similar to the dynamics observed in Fig. 1c . Because trajectories represent a single culture, error bars represent technical error measurements. *p = 0.0006 by a two-tailed, paired t test. Supplementary Fig. 2b except that GFP expression from the UBC promoter was bright rather than dim. Left panel, the frequency of HIV-infected cells (i.e., BFP + ) was determined by flow cytometry at various days post infection. Right panel, single round titers were determined by infecting cells with HIV-BFP at high MOI (81% infected at 3 dpi), harvesting filtered supernatant at 3 dpi and titering on a MT-4s by flow cytometry. b, Multiple and single-round HIV outgrowth in the presence of a lentiviral vector that harbors sequence elements involved in HIV genome packaging (Ψ) and nuclear export (RRE). Similar to F1, the LTR acts as the promoter in this construct (pLG 24 ). Multi-and single-round HIV infections were analyzed as in panel a except that CEMs were transduced with the construct but not sorted. Left panel, 67% of cells were transduced with LTR-GFP while data in right panel were obtained from cells that were 81% transduced with LTR-GFP and 26% infected with HIV-BFP. c, Singleround HIV titers in the presence of F1 in MT-4 cells. An F1-GFP MT-4 cell line was created as described in Supplementary Fig. 2b and infected with HIV-BFP at high MOI (81% of cells were infected at 3 dpi). 3 dpi supernatant titers were determined by flow cytometry. *p = 0.002 by a two-tailed, unpaired Student's t test. d, Spread of HIV in human primary CD4+ T cells in the presence and absence of F1. Human primary CD4+ T cells were co-spinoculated with HIV-BFP and F1-GFP (or mock) and % BFP + cells was measured by flow cytometry at various days post infection. Only 27% of cells were co-infected/transduced with HIV and F1 at 3 dpi. On day 4, p = 0.08 and on day 5, *p = 0.002 by a two-tailed, unpaired Student's t test.
Data represent the average and s.e.m. of three biological replicates. Figure 4 : Engineering F1 to increase transmission for long-term control of HIV outgrowth. a, Transduction competence of engineered F1 VLPs assembled in the presence and absence HIV. Polyclonal cell lines transduced with engineered F1 constructs (single integrations with GFP reporter) were infected with HIV and supernatant was harvested at 3 dpi. F1 cPPT and F1 cPPT Δ VLPs were tittered on permissive MT-4 cells by flow cytometry for GFP. b, Outgrowth of HIV in the presence and absence of the engineered F1 constructs. Polyclonal F1 cPPT -GFP or F1 cPPT Δ-GFP cell lines (same as in a) or a mocktransduced control were infected with HIV-BFP at low MOI. The frequency of BFP + cells was measured by flow cytometry at indicated timepoints. P values were calculated by a twotailed, unpaired Students t test. HIV only vs +F1 cPPT : p = 0.002 (6 dpi), p = 0.004 (8 dpi); HIV only vs +F1 cPPT Δ: p = 0.0009 (6 dpi), p = 0.02 (8 dpi); Inset: Filtered supernatants, harvested at 3 dpi, were titered by flow cytometry (48 after infection of naïve cells). p = 0.005 for titers of HIV only vs each F1 construct by a two-tailed, unpaired Students t test. c, The fraction of packaged RNAs that are derived from HIV or engineered F1 variants. Samples Supplementary Figure 5 : F1 constructs interfere with HIV replication combinatorially through capsid stealing, defective reverse transcriptase activity, and a gag processing defect. a, Outgrowth of HIV in the presence of packaging-incompetent F1. CEM cells were transduced with F1 cPPT Δ or F1 cPPT Δ/ΔΨ so that ~50% of cells harbored the F1 constructs (see inset). Cells were infected with HIV-BFP and the frequency of BFP + cells was measured by flow cytometry at indicated timepoints. b, Relative HIV titers in the absence and presence of packaging-incompetent F1 (related to Fig. 3c ). Assay setup as in panel a except that supernatants were harvested at 3 dpi and titered on the permissive MT-4 cell line. c, Reverse transcriptase activity of pure F1 VLPs. Virions were harvested from 293T transfections with plasmids encoding full-length HIV or F1(Tat+) (the Tat coding sequence was left intact to drive protein expression). HIV and F1 stocks were normalized for capsid protein content and RT activity was measured by the SG-PERT assay 55 . SG-PERT uses virion-associated RT proteins to reverse transcribe a template RNA and the cDNA is quantified by qPCR. Here, the Ct values were converted to fold change relative to HIV stock, which was set at 100% RT activity. d, Gag concentration for stocks of pure HIV virions or F1 VLPs. Samples are same as those in panel c prior to normalization for Gag protein content. e, Western blot analysis of F1 GagPol protein packaging. Left: Schematic of wild-type and F1 gag-pol coding regions with total polyprotein size indicated. Right: Western blot of GagPol proteins in the presence of wild-type protease or a catalytically inactive protease mutant (D25A). 293T cells were transfected with full-length HIV or F1(Tat+) plasmids with and without catalytically active protease domains and supernatant virions were purified by ultracentrifugation before Western analysis with an antibody to p24. The catalytically inactive protease mutation (D25A) 59 enables detection of the GagPol precursors in virions using an antibody to p24. f, Quantifying interference caused by F1 RT trunc protein (related to Fig. 3e ). An RT coding knockout mutation 34 was introduced into the F1 cPPT construct to make F1 cPPT /ΔRT trunc . F1 cPPT -BFP and F1 cPPT /ΔRT trunc -BFP cell lines were infected with HIV-GFP. HIV titers were measured at 3 dpi and percent interference was calculated as in Fig. 3c *p = 0.003 by a twotailed, unpaired Student's t test. g, Gag protein concentration in supernatants in the presence and absence of F1. Mock-transduced or F1 cell lines were infected with HIV and the Gag supernatant concentration was measured by FLAQ assay 56 table) . Box and whiskers plots; black dots represent individual mice, line represents the median, the box extends from the 25 th to 75 th percentile and whiskers denote the maximum to minimum values. P values were calculated using the Mann-Whitney test and significant values are as follows: infected control vs infected F1 cPPT D mice, 0.004; infected control vs infected F1stop cPPT Δ mice. NB: two mice from each infected F1 group were euthanized due to graft versus host disease (GVHD)-a symptom of high levels of CD4+ T cells due to protection from HIV infection-at week one or two post infection. -TGGGACAGCTACAACCATCCC-3'  total rev  5'-GCTGCTGCTTGCTGTGCCTT-3'  WT-specific fwd  5'-GCAGAGACAGGGCAAGAAAC-3'  WT-specific rev  5'-TAGGGAATGCCAAATTCCTG-3'  MS2 fwd  5'-TCCTGCTCAACTTCCTGTCGAG-3'  MS2 final extension: 72° C for 10 min, hold at 4° C. PCR products were analyzed on a 0.8% agarose gel, excised and cleaned using the QIAquick gel extraction kit (Qiagen, 28115) and sent to Elim Biopharm for sequencing using the primers listed above.
Supplementary

Plasmids: "HIV-GFP" is full-length HIV encoding GFP-IRES-nef in the nef reading frame, also called "pNLENG-IRES" 62 and "HIV-BFP" is the NL4-3 infectious clone 63 
Transfection for viral stocks, lentiviral stocks or plasmid co-transfection experiments.
For replication-competent HIV stocks, 293T cells were transfected with plasmid pNLENG1-IRES 62 or pNLENB-IRES. For F1 VLPs assembled in the absence of packaging plasmid, 293T cell were transfected with the indicated F1 construct. To functionally package F1 constructs or lentiviral vectors, the transfer plasmid, packaging plasmid pCMV-dR8.91 65 and pseudotyping plasmid pCMV-VSVG (Addgene, # 8454) were mixed at a mass ratio of 4:10:5, respectively, except for F1 constructs prepared for primary cell transduction which were mixed at a 1:2:1 ratio. HIV:F1 plasmid co-transfection experiments were performed by mixing plasmids at the indicated molar ratios and equalizing the mass across all reactions with excess pUC19. To make the transfection mix, plasmids were diluted in unsupplemented DMEM (i.e., no serum or antibiotics added) to a concentration of 10 ng/mL total DNA and PEI was added to a concentration of 30 µg/mL in a volume ~10% of the total volume in the transfection well or dish (e.g., 200 µl for a 6-well plate with 2 mL media). The transfection mix was vortexed vigorously, incubated for 10 minutes at room temperature, added to cells and incubated overnight. Transfection supernatant was replaced with fresh, supplemented DMEM the following day and supernatant was collected around 48 hours post transfection. To calculate R0, the following caveats were taken into account: 1) not all 5,000 "producer" cells were actually infected (only 12-19%), so the number of producers had to be adjusted to reflect this value. 2) uninfected "producer" cells (i.e., the original F1 cPPT D cells that were not infected with HIV) are also technically susceptible to infection, so we assumed that these cells became infected at the same rate as the "target" cells in the second round of infection and added these cells into the calculation for the number of target cells in the culture. 3) Tat-mCherry expression from the dox-inducible promoter is not fully penetrant, even though the cell line was sorted for mCherry expression. Upon induction with dox, only about 50% of cells fall into the mCherry+ gate. Therefore, we used the mCherry gate to obtain the frequency of HIV or F1 cPPT D secondary infections and then converted this to a number of secondary infections based on the known number of susceptible cells that were added to the culture.
R0 values were calculated as follows: Table 3 for ddPCR primers and probes. All reactions were performed in technical duplicate and samples below the limit of detection (determined by negative controls) were not analyzed for F1 content. Viral loads were determined using primers and probes specific for full-length HIV. The frequency of HIV and F1 RNAs were determined with primer/probe sets specific for total RNA, full-length HIV RNA and F1 RNA. 
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